Vtv Therapeutics
Feb 25, 2025
Alzheimer’s Disease: Navigating the Rising Incidence, Evolving Treatments, and Market Dynamics
Alzheimer’s disease is more than just memory loss—it’s a progressive neurodegenerative disorder that slowly erodes cognition, behavior, and independence. What may begin as occasional forgetfulness or difficulty recalling names can soon escalate into disorientation, personality changes, and an inability to carry out...
Read More...
Mar 05, 2024
Bayer’s New Cardiology Drug Acoramidis; Two Datopotamab Deruxtecan Applications Validated in the EU; AbbVie and OSE Immunotherapeutics Announce Announces Partnership; vTv Therapeutics Makes Major Move With Cadisegliatin; A2 Bio Scores FDA Orphan Drug Designation for its Therapy, A2B530; FDA Fast Track Designation for AlloNK® in Lupus Nephritis
Acoramidis Joins Bayer's Robust Lineup, Boosting Cardiology Solutions Bayer has obtained the exclusive rights to market acoramidis in Europe from Eidos Therapeutics Inc., BridgeBio International GmbH, and BridgeBio Europe B.V. Acoramidis, a highly potent and selective small molecule given orally, functions as a ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
